U.S. weighs charges against ImClone
The federal government is considering charging ImClone Systems Inc. with misleading investors about the status of its cancer drug, the company has said. ImClone said that it had revived a warning
The federal government is considering charging ImClone Systems Inc. with misleading investors about the status of its cancer drug, the company has said. ImClone said that it had revived a warning